A Systematic Review and Meta-Analysis of Lipid Signatures in Post-traumatic Stress Disorder

Veni Bharti1,2, Aseem Bhardwaj2, David A. Elias3,4, Arron W. S. Metcalfe3,5 and Jong Sung Kim1,2*

1 Department of Community Health and Epidemiology, Faculty of Medicine, Dalhousie University, Halifax, NS, Canada, 2 Health and Environments Research Centre (HERC) Laboratory, Faculty of Medicine, Dalhousie University, Halifax, NS, Canada, 3 Canadian Health Solutions Inc., Saint John, NB, Canada, 4 Dalhousie Medicine New Brunswick, Dalhousie University, Halifax, NS, Canada, 5 Canadian Imaging Research Centre, Saint John, NB, Canada

OPEN ACCESS

Edited by: Tamas Kozicz, Mayo Clinic, United States
Reviewed by: Željko Reiner, University Hospital Centre Zagreb, Croatia
Amir Hadi, Isfahan University of Medical Sciences, Iran
*Correspondence: Jong Sung Kim jskim@dal.ca

Specialty section: This article was submitted to Anxiety and Stress Disorders, a section of the journal Frontiers in Psychiatry

Received: 02 January 2022
Accepted: 12 April 2022
Published: 06 May 2022

Citation: Bharti V, Bhardwaj A, Elias DA, Metcalfe AWS and Kim JS (2022) A Systematic Review and Meta-Analysis of Lipid Signatures in Post-traumatic Stress Disorder. Front. Psychiatry 13:847310. doi: 10.3389/fpsyt.2022.847310

Background: Research assessing lipid levels in individuals diagnosed with post-traumatic stress disorder (PTSD) has yielded mixed results. This study aimed to employ meta-analytic techniques to characterize the relationship between the levels of lipid profiles and PTSD.

Methods: We performed meta-analyses of studies comparing profiles and levels of lipids between PTSD patients and healthy individuals by searching Embase, Ovid Medline, Scopus, PsycINFO, and Cochrane databases for the studies until March 2021. Meta-analyses were performed using random-effects models with the restricted maximum-likelihood estimator to synthesize the effect size assessed by standardized mean difference (SMD) across studies.

Findings: A total of 8,657 abstracts were identified, and 17 studies were included. Levels of total cholesterol (TC) (SMD = 0.57 95% CI, 0.27–0.87, \( p = 0.003 \)), low-density lipoprotein (LDL) (SMD = 0.48, 95% CI, 0.19–0.76, \( p = 0.004 \)), and triglyceride (TG) (SMD = 0.46, 95% CI, 0.22–0.70, \( p = 0.001 \)) were found to be higher, while levels of high-density lipoprotein (HDL) (SMD = –0.47, –0.88 to –0.07, \( p = 0.026 \)) were found to be lower in PTSD patients compared to healthy controls. Subgroup analysis showed that TG levels were higher in PTSD patients who were on or off of psychotropic medications, both < 40 and ≥ 40 years of age, and having body mass index of < 30 and ≥ 30 compared to healthy controls.

Interpretation: This work suggested dysregulation of lipids in PTSD that may serve as biomarker to predict the risk. The study will be useful for physicians considering lipid profiles in PTSD patients to reduce cardiovascular morbidity and mortality.

Keywords: post-traumatic stress disorder, psychiatric disorders, major depressive disorder, lipids, fatty acids

INTRODUCTION

Post-traumatic stress disorder (PTSD) is a mental health condition that appears after exposure to a life-threatening or traumatic event or repeated exposure to traumatic events (1). PTSD is characterized by nightmares and flashbacks of previous traumatic events, sleep disturbance, disturbing thoughts, and avoidance of reminders of trauma (2). It has also been found that those
with PTSD have an increased risk of cardiovascular disorder related morbidity (3, 4) and mortality (5). A considerable body of evidence suggests that patients with PTSD often exhibit dysregulated lipid metabolomic profiles (6–20).

When considering the association between the profiles and levels of lipid biomarkers and PTSD, it is worth noting that the human brain comprises 50–60% lipid constituents of its dry weight (21). Almost 80% of the adult brain’s cholesterol is present in myelin forming oligodendrocytes (22). Myelin is important for increasing the speed of electrical impulses along the nerve fiber (23), protection of neurons by insulation (23), protection from oxidative stress (24) and maintaining integrity of the blood brain barrier (25). Lipids play important roles in the brain, including neurogenesis, synaptogenesis, myelin formation, and impulse conduction (26). Availability of cholesterol is one of the limiting factors in synaptogenesis and is vital for continuous synaptogenesis. It is also important for stability of neurotransmitters (27). Both pre-and post-synaptic areas are rich in cholesterol and organize the synaptic proteins. They are essential in maintaining general neurotransmission process (28).

Fatty acids, polyunsaturated fatty acids (PUFA) in particular, act as “fuel partitioners” by downregulating the genes for lipid synthesis while simultaneously upregulating the genes involved in fatty acid oxidation (29). PUFA modulates the electrical current in neurons by regulating ion channel (30, 31). PUFA can also alter the transcription of genes involved in lipid synthesis (32). Pathophysiology of PTSD entails synaptic loss (33), increased myelination (34), and white matter abnormalities (35) and reduction in cortical thickness (36) in the brain suggesting the role of lipids in the pathogenesis of PTSD. Thus, any changes in lipid levels may affect mood and altered lipid patterns may serve as biomarkers for early diagnosis of mood disorders.

Despite the clear theoretical and mechanistic underpinnings, the observational and epidemiological studies reporting the relationship between serum lipid levels and PTSD are controversial. Some studies have shown that PTSD patients have lower total cholesterol (TC) levels (5), high-density lipoprotein (HDL) levels (5, 7, 10–13, 16), low-density lipoprotein (LDL) levels (17) and triglyceride (TG) levels (15); others have reported higher levels of TC (6, 11–14, 17, 19, 37), HDL (9, 15), LDL (6, 8, 9, 11–14, 16), and TG (6, 9, 11–14, 18, 19). Given the inconsistency in the literature and as of yet, the absence of a meta-analysis comparing the lipid profiles and levels between PTSD patients and healthy controls, evidence synthesis in a meta-analysis may be of use. Therefore, the primary aim of this meta-analysis was to assess the profiles and levels of lipid biomarkers reported in studies of individuals with PTSD and discuss the potential roles of lipid and fatty acid parameters in PTSD. Previous studies suggest a direct association between dysregulated lipid and lipoprotein levels with the cardiovascular events (38, 39), therefore making it important to comprehensively synthesize the current evidence examining lipids and fatty acids compared between PTSD patients and healthy individuals. This is the first meta-analysis comparing the profiles and levels of lipid and fatty acid biomarkers as a continuous measure between PTSD patients and healthy controls and will be useful for clinicians in assessing the risk of cardiovascular events in PTSD patients.

**METHODS**

**Search Strategy and Selection Criteria**

We followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines to perform this meta-analysis (40). Five databases including Embase, Ovid Medline, Scopus, PsycINFO, and Cochrane were searched for articles published up to March 2021 using the following keywords: “cholesterol” OR “LDL” OR “HDL” OR “VLDL” OR “triglyceride” OR “apolipoprotein A” OR “apolipoprotein B” OR “docosahexanoic acid” OR “omega 3 fatty acid” OR “omega 6 fatty acid” OR “polyunsaturated acid” OR “triglyceride” AND “post-traumatic stress disorder” OR “PTSD.” A full search strategy is appended in Supplementary Information. Emtree terms were used in Embase database. The search was limited to original research articles and human studies.

Search lists from all databases were imported to Zotero software (2012, United States) and duplications were removed. All studies were imported to Covidence software (2014, United States) for title and abstract screening and full-text screening by two reviewers, VB and AB independently. Any conflicts at either step were resolved by JSK. The gray literature and articles published in any other language than English were excluded manually by reviewers independently.

The original articles measuring the levels of lipids and fatty acids in blood, serum, and plasma of PTSD patients compared with healthy controls were included. Only the studies that diagnosed PTSD patients using any edition of the Diagnostic and Statistical Manual of Mental Disorders and International Classification of Disease (ICD-10) codes were included. Healthy controls were defined as subjects without having any medical conditions and not using any substance of abuse and antihyperlipidemic medication. Studies having PTSD patients of all age groups were included. Studies having any comorbid cardiovascular disorder (CVD), metabolic disorder, and psychiatric disorders were excluded. PTSD induced by any CVD were not included because CVD itself can increase the level of lipids and may introduce bias in the present study. Studies not representing the continuous measure of lipid parameters were also excluded.

**Data Extraction**

Data was extracted manually on Excel sheets by both reviewers VB and AB. The characteristics extracted from each study were the name of the first author, publication year, mean age and standard deviation (SD), number of PTSD patients and control group, mean and SD of TC, LDL, HDL, very-low density lipoprotein (VLDL), TG, BMI, smoking, alcohol intake and antipsychotic and antihyperlipidemic medication status of PTSD group in all studies. The mean values were reported in International System of Units (SI) units.

**Measurement of Inter-Rater Reliability**

Measurement of inter-rater reliability was measured by calculating Cohen’s kappa coefficient using Covidence software. Kappa coefficient was calculated based on proportionate
agreement between two reviewers, random agreement probability, probability of yes/no to select articles.

**Quality Assessment**

Quality assessment of the studies was performed according to New Castle Ottawa (NOS) scale.

**Data Analysis**

Meta and dmetar packages of R Studio statistical software (4.0.0) were used to conduct this meta-analysis. The meta-analysis was performed when two or more studies reported the mean and SD values of lipids in PTSD and healthy control groups (41). The random-effects model with the restricted maximum-likelihood estimator was used to synthesize the effect size across the studies. This model incorporates both within-study and between-study variability (42). Standardized mean difference (SMD) was used to assess the effect size due to the variability of assessment methods used by different studies. SMD was calculated using Cohen’s D (42). Cohen’s D is an effect size used to indicate the standardized difference between two means. The significance level for this meta-analysis model was a p-value below 0.05. Effect sizes 0.2, 0.5, and 0.8 were considered as low, moderate, and high effect, respectively (42). Upper and lower limits of 95% confidence intervals (CI) for Cohen’s effect size were also calculated. Heterogeneity across studies was assessed by Q statistics while inconsistency across studies was assessed by \( I^2 \) value (43). \( I^2 \) value of below 25% was considered as low heterogeneity, 25–75% was considered as moderate, and > 75% was considered as high heterogeneity (43). The total amount of heterogeneity was estimated by heterogeneity variance (\( \tau^2 \)) (43). Publication bias was assessed by Egger’s linear regression test (44). This test is used to calculate the asymmetry of the funnel plot. A \( p < 0.05 \) was considered to show significant asymmetry and publication bias (45). This test was not performed when studies less than 10 were present and represented diagrammatically with funnel plots as recommended by Cochrane Collaboration (43).

Second, we performed subgroup analysis of lipids to determine the effect of age, sex, geography, BMI, and use of antipsychotic medications on lipid levels in PTSD patients. Subgroup analysis was not performed where studies below 10 were presented to avoid the reduction of the power of test (41). We used age as a variable for subgroup analysis because LDL levels rises with age due to reduced hepatic LDL receptor expression, which in turn reduces the capacity for removal of LDL (46). We specifically chose the age groups under and above 40 years because of the previous literature suggesting an increase in LDL concentration after 40 years of age (47). Similarly, sex was chosen as a variable because previous studies have reported that males and premenopausal females have different blood lipid profiles. Men in general have higher LDL, TG, and VLDL concentrations than pre-menopause women (48, 49). We stratified the studies as males only, females only, and both sex studies because some of the studies had almost equal ratio of male and female participants. Studies having both male and female participants were not included in the male and female specific classes because that may interfere with the analysis and may introduce bias when investigating the influence of sex on lipid levels. Genetics and environmental factors also shape the lipid profiles (50) of an individual and that may introduce the difference between lipid profiles in people living in different geographical locations. Obesity is also a risk factor for dyslipidemia and approximately 60–70% people having high BMI are known to have high levels of VLDL, TG, and non-HDL cholesterols (51–54). To understand the potential effect of obesity on lipid levels, we stratified the BMI levels above and below 30 because BMI at and above 30 is considered as obesity (55). We also considered antipsychotic medications as a variable for the subgroup analysis because these medications are reported to increase the TG levels (56) and decrease HDL levels (57).

**RESULTS**

**Study Selection**

Of the 8,657 citations retrieved, we included 17 studies for final data inclusion to compare the levels and profiles of lipids between PTSD patients and healthy controls. The inclusion-exclusion criteria for final study selection are shown in Figure 1. We excluded studies that did not provide lipid levels as continuous measures and studies that included any cardiovascular event as the stressor that induced the PTSD condition and studies that included subjects with other psychiatric disorders comorbid with PTSD. The characteristics of the included studies including author name and year of publication, country, lipid markers studied, number of PTSD patients and healthy controls, mean age and SD of PTSD patients and healthy controls, and medication status are described in Table 1. 40% of the selected studies showed combat-related activities as the stressor that induced PTSD. Measurement of Cohen’s kappa for measuring inter-rater reliability measurement is shown in Table 2. Quality assessment of the studies was performed according to Newcastle Ottawa Scale and are presented in Table 3.

**Meta-Analysis of Lipid Levels in Post-traumatic Stress Disorder**

TC levels were analyzed using data from 9 studies, comprising 463 PTSD patients and 887 healthy controls in Table 4. No changes in the TC levels were found between PTSD patients and healthy controls (SMD = 1.51, 95% CI, −0.94 to 3.96, \( p = 0.194 \)) in the original analysis. We also performed sensitivity analysis to reassess the robustness of the findings for TC in primary meta-analysis (58). TC levels were significantly increased in the PTSD patients compared to controls (SMD = 0.46, 95% CI, 0.12–0.81, \( p = 0.014 \)) (Figure 2A) after removing an outlier study (37). Heterogeneity was found to be high between samples, with \( I^2 \) 83.6%. Closely looking at each study, we found that the study (5) included the TC levels data from medical records rather than testing it at the time of recruitment. Since testing for TC levels may be performed at different frequencies for each individual, this may lead to bias in the data and may shift the values in each group. Second, this study also did not report if lipid levels were measured in serum or plasma. A study has shown that the choice of anticoagulant while making the sample may affect the measurements of lipid profiles (59). As a result, we reassessed our analysis strategy, determining the effect size by excluding this study. After excluding this study,
we found that TC levels remained significant with a larger effect size (SMD = 0.57, 95% CI, 0.27–0.87, \( p = 0.003 \)) (Figure 2A). This reduced the heterogeneity between studies, with \( I^2 = 66.4\% \). We found 9 studies comprising 397 PTSD patients and 441 healthy controls to compare the levels of LDL between PTSD and healthy controls. PTSD patients exhibited significantly high levels of LDL compared to healthy controls (SMD = 0.48, 95% CI, 0.19–0.76, \( p = 0.004 \)) (Figure 2B). No changes in the results were observed when we performed the sensitivity analysis for LDL. We did not find any changes in the HDL levels between PTSD patients and healthy controls (SMD = –0.32, 95% CI, –0.83 to 0.19, \( p = 0.187 \)). There was high heterogeneity between samples, with \( I^2 = 94.4\% \). When the Ahmadi et al. (5) study was removed as an outlier, HDL levels were found to be significantly higher in PTSD patients than healthy controls (SMD = –0.48, 95% CI, –0.88 to –0.07, \( p = 0.026 \)); heterogeneity between studies was still high with \( I^2 = 88.5\% \) (Figure 2C). TG levels were analyzed using data from 10 studies, comprising 737 PTSD patients and 3,820 healthy controls. TG levels were significantly increased in PTSD patients compared to healthy controls (SMD = 0.46, 95% CI, 0.22–0.70, \( p = 0.002 \)) (Figure 2D). There was significant between sample heterogeneity with \( I^2 = 81.1\% \). Egger's test revealed asymmetry of the funnel plot and indicates publication bias with Z-statistic value 4.864 (\( p = 0.0001 \)). After removing the outlier study Lihua et al. (15), TG levels remained significantly high in PTSD patients compared to healthy controls, but heterogeneity among studies was reduced to moderate levels with \( I^2 = 55.5\% \). We did not find any difference in the VLDL between PTSD patients and healthy controls (SMD = 0.83, 95% CI, –0.60 to 2.25, \( p = 0.085 \)). Although in our search strategy we exclusively used the keywords to search for articles comparing apolipoproteins, polyunsaturated fatty acids, and monounsaturated fatty acids, we were not able to find at least two publications measuring these parameters as continuous measures comparing between PTSD patients and healthy controls. Hence, due to the limited availability of the publications, we were not able to perform meta-analysis for these parameters.

**DISCUSSION**

We sought to determine the association between the profiles of lipids and fatty acids and having a diagnosis of PTSD using the first meta-analysis study by comparing a slate of lipid and fatty acid measurements between PTSD and healthy control samples. At first, no changes in the TC levels were observed. However, the levels of TC were found to be significantly high in PTSD patients compared to controls after exclusion of the outlier study (37). While the effect size calculated by SMD ranged from –0.18 to 0.85, this study showed SMD value of 10.36, increasing TC values in PTSD patients at extremely high levels. This may be due to differences in the selection of participant characteristics compared to other studies we included in the analysis of effect size. This study did not select any cutoff values for BMI or measure waist circumference while doing participant selection. Previous studies have found that high BMI and increased body weight are risk factors for dyslipidemia (51–53). Therefore, the lack of control of these variables may have been a significant contributing factor to the unexpected findings in this study. Levels of LDL and TG were found to be higher in PTSD patients than healthy controls. At first, no changes in HDL levels were observed between PTSD patients and healthy controls, but after exclusion of an outlier study by Ahmadi et al. (5), HDL was found to be significantly reduced in PTSD patients compared to healthy controls. It is important to note that this particular study reported the HDL levels from medical records. Due to interindividual differences of lipid testing being done, this may introduce bias in the analysis. We only included studies that measured lipid levels at the time of recruitment. One possibility here relates to previous findings that patients having PTSD show elevated sympathetic nervous system (SNS) activity (60). Activation of the SNS leads to enhanced leptin release, thereby surging lipolysis and lipid mobilization from white adipose tissue. Increased lipolysis leads to augmented release of free fatty acids that are

**Subgroup Analyses**

**Triglyceride**

To better understand the results of the meta-analysis, relevant *a priori* subgroups were investigated (Table 5). Subgroup analysis was performed to analyze the effect of sex, age, geography, use of psychotropic medication, and geographical location on TG levels. Differences in TG concentration levels between PTSD patients and healthy controls were present in the studies performed in males (\( p = 0.0001 \)) but not in females (\( p = 0.097 \)). Similarly, studies involving both sexes with approximately the same ratio also did not show a difference in TG levels (\( p = 0.169 \)). Interestingly, TG levels were found to be higher in PTSD patients in both below 40 years of age (\( p < 0.0001 \)) and 40 years and above (\( p = 0.006 \)). PTSD patients exhibited higher levels of TG levels in the studies performed in both America (\( p < 0.0001 \)), Europe (\( p \leq 0.0001 \)), and Australia (\( p = 0.05 \)) but not in the studies performed in Asia (\( p = 0.493 \)). TG levels were higher in the PTSD patients who were on (\( p = 0.001 \)) or off (\( p = 0.001 \)) on antipsychotic medications and both BMI over 30 (\( p < 0.0001 \)) and BMI less 30 (\( p = 0.0004 \)).
TABLE 1 | Characteristics of studies included in the meta-analysis.

| Sr. no. | References          | Marker                  | N (PTSD, HC) | Age (PTSD, HC) | Medicated |
|---------|---------------------|-------------------------|--------------|----------------|-----------|
| 1       | Talbot et al. (6)   | TC, LDL, TG, VLDL       | 94           | 30.55 ± 6.57   | No        |
|         |                     |                         | (44, 50)     | 30.34 ± 8.11   |           |
| 2       | Tae et al. (7)      | HDL                     | 107          | 45.18 ± 8.05   | No        |
|         |                     |                         | (68, 39)     | 42.7 ± 10.0    |           |
| 3       | Jergović et al. (8) | LDL                     | 101          | 47.12 ± 5.92   | Yes       |
|         |                     |                         | (69, 32)     | 45.56 ± 7.24   |           |
| 4       | Dedert et al. (9)   | HDL, LDL, TG            | 134          | 41.3 ± 11.6    | No        |
|         |                     |                         | (63, 71)     | 39.6 ± 14      |           |
| 5       | Dennis et al. (10)  | HDL                     | 220          | 30.49 ± 5.48   | No        |
|         |                     |                         | (103, 117)   | 27.9 ± 5.52    |           |
| 6       | Karlovic et al. (11)| TC, HDL, LDL, TG       | 82           | 41.3 ± 8.3     | Yes       |
|         |                     |                         | (43, 39)     | 43.8 ± 10.1    |           |
| 7       | Karlovic et al. (12)| TC, HDL, LDL, TG       | 102          | 34 ± 5.4, 35 ± 4.3 | Yes    |
|         |                     |                         | (53, 49)     |               |           |
| 8       | Kulenović et al. (13)| TC, HDL, LDL, TG, VLDL| 100          | 45, 45         | No        |
|         |                     |                         | (50, 50)     |               |           |
| 9       | Maia et al. (14)    | TC, LDL, TG             | 101          | 35.73 ± 7.12   | NA        |
|         |                     |                         | (11, 90)     | 33.11 ± 5.38   |           |
| 10      | Lihua et al. (15)   | HDL, TG                 | 2,967        | 25, 35         | NA        |
|         |                     |                         | (201, 2,666) |               |           |
| 11      | Hamazaki et al. (16)| HDL, LDL                | 30           | 47 ± 16, 36 ± 15 | NA    |
|         |                     |                         | (15, 15)     |               |           |
| 12      | de Vries et al. (17)| TC, LDL                 | 94           | 46 ± 10.4      | Yes       |
|         |                     |                         | (49, 45)     | 46.6 ± 10      |           |
| 13      | Linnville et al. (18)| TG                       | 154          | 61 ± 6, 61 ± 6  | NA        |
|         |                     |                         | (89, 65)     |               |           |
| 14      | Ahmadi et al. (5)   | TC, HDL                 | 637          | 59 ± 9, 58 ± 10 | NA        |
|         |                     |                         | (88, 540)    |               |           |
| 15      | Su et al. (19)      | TC, TG                  | 709          | 17 ± 0.61, 16.9 ± 0.58 | NA   |
|         |                     |                         | (75, 634)    |               |           |
| 16      | Ansari and Ahmed (37)| TC                       | 65           | 35.1 ± 1.6     | NA        |
|         |                     |                         | (50, 15)     | 35.1 ± 1.6     |           |
| 17      | McLeay et al. (95)  | TG                      | 214          | 68.5 ± 4.1     | NA        |
|         |                     |                         | (106, 106)   | 69.2 ± 4.2     |           |

PTSD, post-traumatic stress disorder; HC, healthy control; TC, total cholesterol; LDL, low density-lipoprotein; HDL, High density lipoprotein; TG, triglyceride; VLDL, very low density lipoprotein; NA, not available.

Further transported to the liver and increase the TG production. A previous study has reported that sympathetic denervation in the liver decreased the TG-VLDL secretion (61), suggesting that SNS directly activates the liver lipogenesis. Fatty acid release is increased by stimulating hepatic VLDL-TG production and increased lipolysis in white adipose tissue. Due to the lipolysis of white adipose tissue, free fatty acids are released that are further transported to the liver to increase the production of TG (62). Previous studies have shown that PTSD patients exhibit high levels of the stress hormone cortisol even in recovery phase (63, 64). Cortisol when present in excess, also increases lipolysis and elevates the free fatty acid levels that further increases VLDL secretion and TG storage in the liver (65). Increased free fatty acid levels and cortisol also enhance the activity of HMG-CoA reductase enzyme activity in the liver, stimulating the synthesis of total cholesterol (65). In the presence of high cortisol, LDL-receptor activity is also reduced, leading to high levels of LDL (66, 67). Supporting evidence for this interpretation was found here in the subgroup analysis of BMI where elevated TG levels were present even in lower BMI PTSD samples compared to lower BMI healthy control samples, discussed in more detail in the following section.

Our subgroup analysis for TG showed higher levels of TG in PTSD patients in male-specific studies when compared to healthy controls. No changes were observed in TG levels in female-specific studies and other studies had almost equal ratios of males and females. Our observation is in agreement with a previous study which showed males had higher TG levels than females (68). One of the possible explanations of having higher TG levels in men may be due to the high waist/hip ratio in men compared to women. High waist/hip ratio is an indicator of visceral fat and could be a major determinant of hepatic exposure to free fatty acids released by portal adipose tissues (69). However, due to the scarcity of data on waist/hip ratio, we were not able to analyze this data. Another study reported that the proportion of men who were 45 or over 45 years of age...
having low testosterone levels had an increase in TG/HDL ratio quartile (70). Low testosterone levels are associated with high deposition of visceral fat, central obesity, and other metabolic syndromes including insulin resistance (71, 72). When we closely looked at our analysis, 4 out of 6 male-specific studies were reported in males over 40 years, suggesting a possibility of reduced testosterone that may increase TG levels and reduce HDL levels. Previous studies have suggested that the luteal phase in females is shown to have reduced TG levels than follicular phase (73). Studies analyzed in the present work did not report in which phase of the menstrual cycle the sample was taken from female participants. Our study also indicated higher TG levels in PTSD patients than healthy controls in both groups with BMI below 30 and 30 and above. BMI is a measure to determine the weight range of the body by calculating body weight and height. This parameter classifies individuals as underweight, normal, overweight, or obese. However, one of the limitations of this scale is that it does not demonstrate how much fat and muscle one has in the body. Measurement of waist circumference is another tool that can be used to determine central obesity and can also be used to determine the waist/hip ratio. Indeed, it has been shown that waist circumference is positively correlated with TG levels (74). Although we did not perform subgroup analysis of TC, LDL, and HDL to investigate the effects of BMI on these parameters in PTSD patients due to the presence of less than 10 studies, our raw data suggests increased TC and LDL, and decreased HDL in PTSD patients with BMI of 30. Increased central obesity and visceral tissues are known to be correlated with high TC and LDL levels, and reduced HDL levels (74). People with high waist circumference have high TG accumulated in the fat tissues that may lead to increased conversion of TG-rich LDL to small, dense LDL with longer half-life by hepatic lipase enzymes. When TG levels are high, HDL particles are enriched with TG that can be catabolized faster than cholesteryl esters containing HDL particles, thereby reducing the levels of HDL upon increase in TG levels (75).

Our study also showed higher TG levels in the PTSD patients than controls in American and European studies than the studies performed in Asia. This may be explained by the fact reported in a previous study which reported that Asians exhibit more somatic symptoms such as reduced appetite when depressed than non-Asians (76). Since PTSD patients represent depressed mood, lesser food intake in these patients may lead to reduced TG in

---

**TABLE 2** Measurement of inter-rater reliability at title and abstract level

| Reviewer 1 | Reviewer 2 | Yes | No |
|------------|------------|-----|----|
|            | Yes        | 66  | 19 |
|            | No         | 35  | 7,559 |

Proportionate agreement: 0.99296
Probability of yes: 0.00014
Probability of no: 0.97592
Random agreement: 0.97606
Cohen's kappa coefficient: 0.70

**TABLE 3** Quality assessment of studies

| Sr. No. | References | Study type      | Selection | Comparability | Outcome | Total |
|---------|------------|-----------------|-----------|---------------|---------|-------|
| 1       | Talbot et al. (6) | Cross-sectional | 4         | 1             | 3       | 8     |
| 2       | Tae et al. (7)   | Prospective cohort | 3         | 1             | 3       | 7     |
| 3       | Jergović et al. (8) | Case control | 4         | 1             | 2       | 7     |
| 4       | Dedret et al. (9) | Cross-sectional | 4         | 1             | 3       | 8     |
| 5       | Dennis et al. (10) | Cross-sectional | 4         | 1             | 3       | 8     |
| 6       | Karlovic et al. (11) | Cross-sectional | 3         | 1             | 3       | 7     |
| 7       | Karlovic et al. (12) | Cross-sectional | 3         | 1             | 3       | 7     |
| 8       | Kulevović et al. (13) | Cross-sectional | 3         | 1             | 3       | 7     |
| 9       | Maia et al. (14) | Cross-sectional | 3         | 1             | 3       | 7     |
| 10      | Lihua et al. (15) | Cross-sectional | 4         | 1             | 3       | 8     |
| 11      | Hamazaki et al. (16) | Cohort | 4         | 1             | 3       | 8     |
| 12      | de Vries et al. (17) | Cross-sectional | 4         | 1             | 3       | 8     |
| 13      | Linville et al. (18) | Cross-sectional | 3         | 1             | 3       | 7     |
| 14      | Ahmadi et al. (19) | Cross-sectional | 4         | 1             | 3       | 8     |
| 15      | Su et al. (19) | Cross-sectional | 5         | 1             | 3       | 9     |
| 16      | Ansari and Ahmed (37) | Cohort | 3         | 1             | 2       | 6     |
| 17      | McLeay et al. (85) | Cross-sectional | 5         | 1             | 3       | 9     |
TABLE 4 | Meta-analysis of lipid levels in PTSD.

| Lipid/fatty acid/lipid regulatory protein | Q statistic (DF; p-value) | SMD (95%CI) | p-value | I² (%) | τ² | Egger’s test Z-statistic (p-value) |
|-----------------------------------------|--------------------------|-------------|---------|--------|----|-------------------------------|
| TC                                      | 17.86 (6; 0.006)         | 0.57        | 0.003   | 66.4   | 0.07 | NA                            |
| LDL                                     | 23.48 (8; 0.002)         | 0.48        | 0.004   | 65.9   | 0.09 | NA                            |
| HDL                                     | 60.79 (7; < 0.0001)      | –0.48       | 0.026   | 88.5   | 0.69 | NA                            |
| TG                                      | 47.67 (8; < 0.0001)      | 0.46        | 0.001   | 81.1   | 0.08 | 4.864 (p = 0.0001)           |
| VLDL                                    | 0.56 (1; 0.4538)         | 0.83        | 0.085   | 0      | 0   | NA                            |

TC, total cholesterol; LDL, low density-lipoprotein; HDL, high density lipoprotein; TG, triglyceride; VLDL, very low density-lipoprotein; NA, not available.

Egger’s test was not performed for parameters having < 10 studies.

FIGURE 2 | (A) Forest plot showing lipid parameter Total Cholesterol (TC) levels in the patients with Post-traumatic Stress Disorder (PTSD) and healthy controls. The black squares correspond to the standardized mean difference (SMD) of each study and horizontal bars represent 95% CI of each study. (B) Forest plot showing lipid parameter Low Density-Lipoprotein (LDL) levels in the patients with Post-traumatic Stress Disorder (PTSD) and healthy controls. The black squares correspond to the standardized mean difference (SMD) of each study and horizontal bars represent 95% CI of each study. (C) Forest plot showing lipid parameter High Density-Lipoprotein (HDL) levels in the patients with Post-traumatic Stress Disorder (PTSD) and healthy controls. The black squares correspond to the standardized mean difference (SMD) of each study and horizontal bars represent 95% CI of each study. (D) Forest plot showing lipid parameter Triglyceride (TG) levels in the patients with Post-traumatic Stress Disorder (PTSD) and healthy controls. The black squares correspond to the standardized mean difference (SMD) of each study and horizontal bars represent 95% CI of each study.

Asian studies. However, the studies included in the meta-analysis did not report dietary intake. Another possible reason for higher TG in non-Asian studies than Asian studies may be due to the presence of a low number of Asian studies. Out of 10 studies representing a comparison of TG levels between PTSD patients and healthy controls, only 2 studies were performed in Asia. The low number of Asian studies may be due to the lower risk of Asians for the development of PTSD upon exposure to the traumatic events (77).

Our study also reported higher TG levels in the PTSD patients who were both on or off of antipsychotic medications, when compared to healthy controls. One of the previous studies
TABLE 5 | Subgroup analyses for studies included in the analysis that assessed the triglyceride (TG) levels in PTSD patients vs. Healthy Controls.

| Subgroup                              | No. of studies | SMD (95% CI)          | p-value  | I²  |
|---------------------------------------|----------------|-----------------------|----------|-----|
| **Sex**                               |                |                       |          |     |
| Males                                 | 6              | 0.57 (0.27–0.86)      | 0.0001   | 0.88|
| Females                               | 1              | 0.28 (–0.05 to 0.62)  | 0.097    | NA  |
| Both sexes                            | 3              | 0.29 (–0.12 to 0.70)  | 0.169    | 0.87|
| **Age**                               |                |                       |          |     |
| < 40 years                             | 5              | 0.48 (0.19–0.77)      | < 0.0001 | 0.64|
| ≥ 40 years                             | 5              | 0.45 (0.12–0.78)      | 0.006    | 0.87|
| **Geography**                         |                |                       |          |     |
| America                               | 4              | 0.45 (0.20–0.70)      | 0.0004   | 0.35|
| Europe                                | 3              | 0.84 (0.68–0.99)      | <0.0001  | 0   |
| Asia                                  | 2              | 0.12 (–0.23 to 0.49)  | 0.930    | 0.85|
| Australia                             | 1              | 0.26 (0.003–0.53)     | 0.05     | 0   |
| **Use of psychotropic drugs**         |                |                       |          |     |
| Psychotropic medications              | 2              | 0.55 (0.22–0.89)      | 0.001    | 0.66|
| No psychotropic medications           | 3              | 0.64 (0.24–1.04)      | 0.001    | 0.71|
| **BMI**                               |                |                       |          |     |
| ≥30                                   | 2              | 0.27 (0.25–0.29)      | <0.0001  | 0   |
| <30                                   | 7              | 0.51 (0.22–0.79)      | 0.0004   | 0.86|

has suggested that the patients having psychiatric disorders present metabolic dyslipidemia along with features of metabolic syndrome and other risk factors for cardiovascular disorder (78). Antipsychotic medications including but not limited to olanzapine, quetiapine, clozapine, amitriptyline, are reported to increase metabolic disturbances including high TG levels (78, 79). Previous studies reported that these medications elevate lipid levels by stimulating the sterol regulatory element binding protein that increases gene expression related to lipid biosynthesis (80, 81). In our study, 20% of the studies reported that their participants were on antipsychotics, while 30% reported no use of antipsychotics by PTSD patients. The other 50% of the studies did not report data on the current use of antipsychotics by PTSD patients. Interestingly, two studies that reported no use of antipsychotics and higher TG levels in PTSD patients showed that these patients were current smokers (11, 12) and one of these two studies reported the use of alcohol by these patients.9 This observation is consistent with previous studies suggesting that smoking lead to high serum TG levels (82, 83). Alcohol intake also increases the synthesis of VLDL particles in the liver, which serves as the main source of TG production; thereby increasing the level of TG (84).

TG levels were found to be higher in the PTSD patients both in below 40 and 40 and above years of age than when compared to healthy controls. In older age, fat accumulation starts increasing that may lead to increases in TG levels. Diet, alcohol intake, lifestyle, smoking, central obesity, and fat content all contribute to increases in TG levels. However, our reviewed studies did not report data on these parameters, limiting our analysis for finding the reasons behind increased TG levels in younger age counterparts.

The mechanism for lipid dysregulation and its effects on swinging mood in PTSD is not well understood. It has been proposed that cholesterol present in the form of “lipid rafts” in the synaptosomal membrane might determine the number of serotonin receptors (85) and dopamine transporters (51, 86), thus making an impact on neurotransmitter signaling. Activation of these receptors are important for the regulation of mood (87). Patients having PTSD have shown decreased concentrations of serotonin in the dorsal and median raphe nuclei and increased dopamine levels (88). The dysregulation of these neurotransmitters interferes with the fear conditioning circuits by disturbing the dynamics between the amygdala and hippocampus and by affecting the mesolimbic system (88). Fear conditioning plays a major role in PTSD. In PTSD, fear learned in a traumatic situation can be triggered by a variety of provocations that resemble the initial trauma (89). Thus, dysregulated lipids may affect neurotransmitter signaling, further affecting mood.
A study published in 2018 suggested that PTSD patients represent social impairments that make their differential diagnosis difficult. As anxiety, recurrent suicidal ideations, negative feelings, and HDL levels. MDD and PTSD both share certain symptoms such as an increase in total cholesterol, LDL, and TG, and a reduction in levels (90). However, our results indicate that PTSD patients show patients. MDD patients showed a reduction in TC levels, increase compared to healthy controls (90), this may explain decrease in TC in contrast to PTSD patients who show increased TC. Second, this work will be useful for physicians when considering the risk while assessing lipid levels in PTSD patients to reduce the cardiovascular morbidity and mortality in these patients. More mechanistic studies are required to understand the association between lipid levels and PTSD. Since the number of studies to understand the source of heterogeneity was small for TC, LDL, and HDL levels, more longitudinal studies are required to understand the levels of these parameters in PTSD patients. Further studies are required to study the predictive values of lipid levels to assess the risk of cardiovascular mortality and morbidity in PTSD.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

**AUTHOR CONTRIBUTIONS**

VB and AB selected the abstracts and full-text articles, extracted the data, and performed statistical analysis. VB and JK designed the study, analyzed, interpreted the data, drafted, and finalized the manuscript. JK, DE, and AM conceived the original research idea, participated in data interpretation, theoretical interpretation, and description, and gave input on report drafts. All authors contributed to the article and approved the submitted version.

**FUNDING**

This research was conducted with funding from the Mitacs Accelerate Postdoctoral Fellowship, investment from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP)—Canadian International Innovation Program (CIIP), and the Scientific Research and Experimental Development (SR&ED) Tax Incentive Program from the Government of Canada.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyt.2022.847310/full#supplementary-material
REFERENCES

1. Friedman MJ, Resick PA, Bryant RA, Brewin CR. Considering PTSD for DSM-5. *Depress Anxiety.* (2011) 28:750–69. doi: 10.1002/da.20767

2. van der Kolk BA, Pelcovitz D, Roth S, Mandel FS, McFarlane A, Herman JL. Dissociation, somatization, and affect dysregulation: the complexity of adaptation of trauma. *Am J Psychiatry.* (1996) 153(Suppl. 7):83–93. doi: 10.1176/aip.153.7.83

3. Bedi US, Arora R. Cardiovascular manifestations of posttraumatic stress disorder. *J Natl Med Assoc.* (2007) 99:642–9.

4. Blanchard EB. Elevated basal levels of cardiovascular responses in Vietnam veterans with PTSD: a health problem in the making? *J Anxiety Disord.* (1990) 4:233–7. doi: 10.1016/0887-6185(90)90015-2

5. Ahmadi N, Hajsadeghi F, Mirshkarlo HB, Budoff M, Yehuda R, Ebrahimi R. The impact of race on metabolic disease risk factors in women with and without posttraumatic stress disorder. *J Clin Psych Med Settings.* (2013) 20:46–55. doi: 10.1016/j.sjpsy.2018.04.058

6. Talbot LS, Rao MN, Cohen BE, Richards A, Inslicht SS, O'Donovan A, et al. Circulating levels of hormones, lipids, and immune mediators in posttraumatic stress disorder – a 3-month follow-up study. *Front Psychiatry.* (2015) 6:49. doi: 10.3389/fspyt.2015.00049

7. Dedert EA, Harper LA, Calhoun PS, Dennis MF, Beckham JC. The impact of race on metabolic disease risk factors in women with and without posttraumatic stress disorder. *J Clin Psych Med Settings.* (2013) 20:46–55. doi: 10.1016/j.sjpsy.2018.04.058

8. Jergović M, Bendelja K, Šavić Mlakar A, Vojvoda V, Aberle N, Jovanovic T, et al. Lipids in the nervous system: from biochemistry and molecular biology to patho-physicsiology. *Biochim Biophys Acta.* (2015) 1851:51–60. doi: 10.1016/j.bbad.2014.08.011

9. Liu J-P, Tang Y, Zhou S, Toh BH, McLean C, Li H. Cholesterol involvement in posttraumatic stress disorder – a 3-month follow-up study. *Am J Psychiatry.* (2015) 172:369–74. doi: 10.1176/psyc.2015.08.020

10. Ahmad N, Hajsadeghi F, Mirshkarlo HB, Budoff M, Yehuda R, Ebrahimi R. The impact of race on metabolic disease risk factors in women with and without posttraumatic stress disorder. *J Clin Psych Med Settings.* (2013) 20:46–55. doi: 10.1016/j.sjpsy.2018.04.058

11. Karlovic D, Martinac M, Marcinko D. Serum lipid concentrations in Croatian veterans with post-traumatic stress disorder, post-traumatic stress disorder comorbid with major depressive disorder, or major depressive disorder. *J Korean Med Sci.* (2004) 19:431–6. doi: 10.3346/jkms.2004.19.3.431

12. Karlovic D, Martinac M, Buljan D, Zoričić Z. Relationship between serum lipid concentrations and posttraumatic stress disorder symptoms in soldiers with combat experiences. *Acta Med Okayama.* (2004) 58:23–7. doi: 10.18926/AMO/32118

13. Lahav D, Marmar CR, Mendlovicz MV, Metzler T, Nöbrega A, Peres MC, et al. Abnormal serum lipid profile in Brazilian police officers with post-traumatic stress disorder. *J Affect Disord.* (2008) 107:259–63. doi: 10.1016/j.jad.2007.08.013

14. Li S, Sun G, Guo QW, Yang M, Chen X, Lin J, et al. Posttraumatic stress disorder augments plasma triglycerides in TH1 homozygotes of rs495225 at growth hormone secretagogue receptor gene. *Biochem Genet.* (2019) 57:273–88. doi: 10.1007/s10528-018-9890-5

15. Levine AB, Levine LM, Levine TB. Posttraumatic stress disorder and cardiometabolic disease. *Cardiology.* (2014) 127:1–19. doi: 10.1159/000354910

16. Bruce KD, Zsombo A, Eckel RH. Lipid processing in the brain: a key regulator of systemic metabolic balance. *Front Endocrinol.* (2017) 8:60. doi: 10.3389/fendo.2017.00060

17. Bjorkhem I, Meany S. Brain cholesterol: long secret life behind a barrier. *Artheroscler Thromb Vasc Biol.* (2004) 24:806–15. doi: 10.1161/01.ATV.0000120374.59826.1b

18. Mukherjee C, Kling T, Russo B, Michbach K, Kiss E, Schifferer M, et al. Oligodendrocytes provide antioxidant defense function for neurons by secreting ferritin heavy chain. *Cell Metab.* (2020) 32:259–72. doi: 10.1016/j.cmet.2020.05.019

19. Ansari M, Ahmed S. Calcium channel blocker verapamil: a new intervention for high cholesterol levels in patients with PTSD. *Turkish J Endocrinol Metab.* (2007) 11:93–7.
on lipid profile in plasma samples as measured by an automated chemical analyzer. *Biomed Res Clin Pract.* (2017) 2:1–4.

38. Braden C, Park J, Wiaderekiewicz K, Kobayashi I, Mellman TA, Marvar PJ. Autonomic and inflammatory consequences of posttraumatic stress disorder and the link to cardiovascular disease. *Am J Physiol Regul Integr Comp Physiol.* (2015) 309:E315–21. doi: 10.1152/ajpregu.00343.2014

39. Bruinsoever E, Pei L, Ackermans MT, Poppen E, Borgers AJ, Kwakkel J, et al. Hypothalamic neuropeptide Y (NPY) controls hepatic VLDL-triglyceride secretion in rats via the sympathetic nervous system. *Diabetes.* (2012) 61:1043–50. doi: 10.2337/db11-1142

40. Geelijng JJ, Boon MR, Kooijman S, Parlevliet ET, Havekes LM, Romijn JA, et al. Sympathetic nervous system control of triglyceride metabolism: novel concepts derived from recent findings. *J Lipid Res.* (2014) 55:180–9. doi: 10.1194/jlr.R045013

41. Elzinga BM, Schmahl CG, Vermetten E, Dyck RV, Bremner JD. Higher cortisol levels following exposure to traumatic reminders in abuse-related PTSD. *Neuropsychopharmacology.* (2003) 28:1656–65. doi: 10.1083/jn.1300226

42. Young EA, Breslau N. Cortisol and catecholamines in posttraumatic stress disorder: an epidemiologic community study. *Arch Gen Psychiatry.* (2004) 61:394–401. doi: 10.1001/archpsyc.61.4.394

43. Brindley DN, McCann BS, Niaura R, Stoney CM, Suarez EC. Stress and lipoprotein metabolism: modulators and mechanisms. *Metabolism.* (1993) 42(Suppl. 1):3–15. doi: 10.1016/0026-0495(93)90255-m

44. Djuhrus CB, Gravholt CH, Nielsen S, Mangel A, Christiansen JS, Schmitz OE, et al. Effects of cortisol on lipolysis and regional interstitial glycerol levels in humans. *Am J Physiol Endocrinol Metabol.* (2002) 283:E172–7. doi: 10.1152/ajpendo.00544.2001

45. Al Rayyes O, Wallmark A, Florén CH. Additive inhibitory effect of hydrocortisone and cyclosporine on low-density lipoprotein receptor activity in cultured HepG2 cells. *Hepatology.* (1997) 26:967–71. doi: 10.1002/hep.10260425

46. Assmann G, Schulte H. The prospective cardiovascular münster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. *Am Heart J.* (1988) 116:1713–24. doi: 10.1016/0002-8703(88)90220-7

47. Seidell JC, Cigolini M, Charzewski J, Ellsinger BM, Björntorp P, Hautvast JGAJ, et al. Fat distribution and gender differences in serum lipids in men and women from four European communities. *Atherosclerosis.* (1991) 87:203–10. doi: 10.1016/0021-9150(91)90022-u

48. Chung TH, Kwon YJ, Lee YJ. High triglyceride to HDL cholesterol ratio is associated with low testosterone and sex hormone-binding globulin levels in middle-aged and elderly men. *Aging Male.* (2020) 23:93–7. doi: 10.1080/13685538.2018.1501015

49. Laaksonen DE, Niskaan L, Punnoken K, Nyssönen K, Tuomainen TP, Vållkonen VP, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. *Diabetes Care.* (2004) 27:1036–41. doi: 10.2337/diacare.27.5.1036

50. Brand JS, Rovers MM, Yeap BB, Schneider HJ, Tuomainen TP, Haring R, et al. Testosterone, sex hormone-binding globulin and the metabolic syndrome in men: an individual participant data meta-analysis of observational studies. *PLoS One.* (2014) 9:e100049. doi: 10.1371/journal.pone.0100049

51. Magkos F, Patterson BW, Mittendorfer B. No effect of menstrual cycle phase on basal very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics. *Am J Physiol Endocrinol Metabol.* (2006) 291:E1243–9. doi: 10.1152/ajpendo.00246.2006

52. Darsini D, Hamidah H, Suryo ESG, Kastelein JP. Obesity and dyslipidemia. *Med Clin North Am.* (2011) 95:893–902.

53. Franssen R, Nomajemi H, Stroes ESG, Kastelein JP. Obesity and dyslipidemia. *Med Clin North Am.* (2011) 95:893–902.

54. Xiao C, Dash S, Morgantini C, Hegele RA, Lewis GF. Pharmacological targeting of the atherogenic dyslipidemia complex: the next frontier in CVD prevention beyond lowering LDL cholesterol. *Diabetes.* (2016) 65:1786–78. doi: 10.2337/db16-0046

55. Garrow JS, Webster J. Quetelet's index (W/H2) as a measure of fatness. *Int J Obes.* (1985) 9:147–53.

56. Raffin M, Gianetti M, Consoli A, Bonnot O, Menard ML, Askenazy F, et al. Management of adverse effects of second-generation antipsychotics in youth. *Curr Treat Options Psychiatry.* (2014) 1:84–105. doi: 10.1007/s40501-013-0007-9

57. Crichton GE, Elias MF, Robbins MA. Association between depressive symptoms, use of antidepressant medication and the metabolic syndrome: the Maine-Syracuse study. *BMC Public Health.* (2016) 16:502. doi: 10.1186/s12889-016-3170-2

58. Thabane L, Mbuagbaw L, Zhang S, Samaan Z, Marucci M, Ye C, et al. A tutorial on sensitivity analyses in clinical trials: the what, why, when and how. *BMC Med Res Methodol.* (2013) 13:92. doi: 10.1186/1471-2288-13-92

59. Anto E, Kwame W, Owiredu B, Obirikorang C, Acheampong E, Amankwa B, et al. Influence of K2EDTA, sodium citrate and lithium heparin anticoagulants

Frontiers in Psychiatry | www.frontiersin.org 11 May 2022 | Volume 13 | Article 847310
78. Jakovljevic M, Reiner Z, Milicic D. Mental disorders, treatment response, mortality, and serum cholesterol: a new holistic look at old data. *Psychiatr Danub.* (2007) 19:270–81.

79. Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. *Lancet Psychiatry.* (2020) 7:64–77. doi: 10.1016/S2215-0366(19)30416-X

80. Ferno J, Vik-Mo A, Jassim G, Håvik B, Berge K, Skrede S, et al. Acute clozapine exposure in man induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver. *Psychopharmacology.* (2008) 203:73–84. doi: 10.1007/s00213-008-1370-x

81. Jassim G, Skrede S, Vázquez MJ, Wergedal H, Vik-Mo AO, Lunder N, et al. Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat. *Psychopharmacology* (Berl). (2012) 219:783–94. doi: 10.1007/s00213-011-2397-y

82. Craig WY, Palomaki GE, Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. *BMJ.* (1989) 298:784–8. doi: 10.1136/bmj.298.6676.784

83. Freeman DJ, Griffin BA, Murray E, Lindsay GM, Gaffney D, Packard CJ, et al. Smoking and plasma lipoproteins in man: effects on low density lipoprotein cholesterol levels and high density lipoprotein subtraction distribution. *Eur J Clin Invest.* (1993) 23:630–40. doi: 10.1111/j.1365-2265.1993.tb00724.x

84. de Wiel AD. The effect of alcohol on postprandial and fasting triglycerides. *Psychopharmacology.* (2012) 219:783–94. doi: 10.1007/s00213-011-2397-y

85. Engelberg H. Low serum cholesterol and suicide. *Lancet.*

86. Jakovljevic M, Reiner Z, Milicic D. Mental disorders, treatment response, mortality, and serum cholesterol: a new holistic look at old data. *Psychiatr Danub.* (2007) 19:270–81.

87. Sun S, Yang S, Mao Y, Jia X, Zhang Z. Reduced cholesterol is associated with...

88. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. *Circulation Res.* (2005) 96:1221–32. doi: 10.1161/01.RES.0000170946.56981.5c

89. Dunsmoor JE, Paz R. Fear generalization and anxiety: behavioral and neural mechanisms. *Biol Psychiatry.* (2015) 78:336–43. doi: 10.1016/j.biopsych.2015.04.010

90. Bharti V, Bhardwaj A, Hood K, Elias DA, Metcalfe AWS, Kim JS. A systematic review and meta-analysis of lipid metabolomic signatures of major depressive disorder. *J Psychiatr Res.* (2021) 139:197–205. doi: 10.1016/j.jpsychires.2021.05.036

91. Aspesi D, Pinna G. Could a blood test for PTSD and depression be on the horizon? *Expert Rev Proteomics.* (2018) 15:983–1006. doi: 10.1080/14789450.2018.1544894

92. Jankowski CM, Gozansky WS, Van Pelt RE, Wolfe P, Schwartz RS, Kohut WM. Oral dehydroepiandrosterone replacement in older adults: effects on central adiposity, glucose metabolism and blood lipids. *Clin Endocrinol.* (2011) 75:456–63. doi: 10.1111/j.1365-2265.2011.04073.x

93. Srinivasan M, Irving BA, Frye RL, O’Brien P, Hartman SJ, McConnell JP, et al. Effects on lipoprotein particles of long-term dehydroepiandrosterone in elderly men and women and testosterone in elderly men. *J Clin Endocrinol Metab.* (2010) 95:1617–25. doi: 10.1210/jc.2009-2000

94. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. *Circulation Res.* (2005) 96:1221–32. doi: 10.1161/01.RES.0000170946.56981.5c

95. McLeay SC, Harvey WM, Romaniuk MN, Crawford DH, Colquhoun DM, Young RM, et al. Physical comorbidities of post-traumatic stress disorder in Australian Vietnam War veterans. *Med J Aust.* (2017) 206:251–7. doi: 10.5694/mja16.00935

**Conflict of Interest:** DE was President and Chief Executive Officer of Canadian Health Solutions Inc. Canadian Health Solutions is currently researching potential clinical indications correlated with a diagnosis of PTSD. The current research has no direct commercial relationship with that work. AM was employed by Canadian Health Solutions Inc.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**Copyright © 2022 Bharti, Bhardwaj, Elias, Metcalfe and Kim. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.**